Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
30.28B
Market cap30.28B
Price-Earnings ratio
-22.49
Price-Earnings ratio-22.49
Dividend yield
Dividend yield
Average volume
1.84M
Average volume1.84M
High today
$143.61
High today$143.61
Low today
$139.92
Low today$139.92
Open price
$142.63
Open price$142.63
Volume
470.37K
Volume470.37K
52 Week high
$212.75
52 Week high$212.75
52 Week low
$60.40
52 Week low$60.40

Stock Snapshot

The current Insmed Incorporated(INSM) stock price is $140.46, with a market capitalization of 30.28B. The stock trades at a price-to-earnings (P/E) ratio of -22.49.

On 2026-03-20, Insmed Incorporated(INSM) stock traded between a low of $139.92 and a high of $143.61. Shares are currently priced at $140.46, which is +0.4% above the low and -2.2% below the high.

The Insmed Incorporated(INSM)'s current trading volume is 470.37K, compared to an average daily volume of 1.84M.

In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.

In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.

INSM News

Simply Wall St 10h
How Brinsupri’s US$28 Million Launch And Analyst Interest At Insmed Has Changed Its Investment Story

In recent weeks, Insmed has attracted fresh attention as Jefferies initiated coverage with a positive view, while Artisan Partners highlighted the company’s rol...

How Brinsupri’s US$28 Million Launch And Analyst Interest At Insmed Has Changed Its Investment Story
Simply Wall St 2d
Brinsupri Launch Gives Insmed A New Respiratory Revenue Pillar

Insmed (NasdaqGS:INSM) has launched Brinsupri, also known as brensocatib, for non cystic fibrosis bronchiectasis. Brinsupri is the first approved therapy for t...

Brinsupri Launch Gives Insmed A New Respiratory Revenue Pillar
Simply Wall St 3d
Is It Too Late To Consider Insmed After Its 85% One-Year Surge?

Wondering whether Insmed at around US$144.60 a share looks expensive or still has room to run? This breakdown will help you connect the recent share price with...

Is It Too Late To Consider Insmed After Its 85% One-Year Surge?

Analyst ratings

95%

of 21 ratings
Buy
95.2%
Hold
4.8%
Sell
0%

More INSM News

TipRanks 4d
Insmed assumed with a Buy at Jefferies

Jefferies assumed coverage of Insmed (INSM) with a Buy rating and a price target of $228, up from $219. Insmed is to the respiratory space like Vertex Pharmaceu...

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.